News

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

Technology offers increased usability, safety, and accuracy in MIGS procedures.

Extended daylight hours and plentiful outdoor space make Stockholm a memorable destination for meeting attendees

Ella Faktorovich, MD, sat with Ophthalmology Times to discuss an anti-inflammatory treatment protocol she has been using to treat recurrent erosions after corneal refractive surgery.

The pharmaceutical candidate is being evaluated as a potential treat for nAMD.

Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a unique case of a 15-year-old who showed signs of meningioma with epithelial whirls and some psammoma bodies in the eye.

IKA Keratoconus Symposium and Controversies in Modern Eye Care shone brightly in May

42nd Annual Meeting in Stockholm, the Venice of the North

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody for the treatment of wet AMD, DME and RVO.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness.

The SimVis Gekko eye dominance strength test may change the standard of care.

Patients with corneal astigmatism underwent phacoemulsification and rotationally asymmetric multifocal IOL implantation

Durga Borkar, MD, MMCi, recently discussed the quality data (Qdata, Verana Health) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data.

Educational resources include handouts, videos and a dedicated webpage on the proper way to use eye drops

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular edema.

Following the MAA in Europe, Altos Biologics plans to pursue approval in target markets including Korea

The company expects approval from the EMA by 2025.

From amniotic membrane grafting to neurotization.

Faricimab is already approved in the EU and UK for neovascular age-related macular degeneration and diabetic macular oedema

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

The drug is a biosimilar for aflibercept 2 mg (Eylea)

Repeated 0.1-ml intravireal injections of lampalizumab, antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D, seem to be associated with a low risk of elevated IOP

The biosimilar was approved for treating patients with age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

During interview earlier this year, we asked leaders in the retina field would tell residents and medical students as they train for the next decades in retinal care. Here's what 2 of them had to say.

Plasma emission for blepharitis, meibomian gland dysfunction, and dry eye disease.

Apellis will seek re-examination from the CHMP following the opinion